Adam S. Kittai, MD

From sequencing decisions to economics of care, Adam Kittai, MD, offers a wide-ranging look at top unresolved questions in CLL treatment today.

Adam Kittai, MD, reviews AMPLIFY data supporting acalabrutinib-venetoclax (AV) for CLL, citing strong safety and survival outcomes for select patients.

From overtreating good-risk patients to searching for a cure, Adam Kittai, MD, Perlmutter Cancer Center, outlines where CLL management still falls short.

Adam Kittai, MD, breaks down the evolving landscape of CLL sequencing—from venetoclax retreatment to triplet regimens.

Adam Kittai, MD, weighs the favorable safety profile of acalabrutinib plus venetoclax against lingering unknowns on long-term efficacy and high-risk patients.

Time-limited acalabrutinib plus venetoclax improves outcomes vs chemoimmunotherapy, offering the first FDA-approved all-oral fixed-duration CLL option, explains Adam Kittai, MD.

Experts discuss future directions of BTK inhibitors.

A panel of specialists discuss patient access advocacy for BTK inhibitors.

A group of experts discuss implications for patient access in CLL.

A panel of experts discuss navigating access challenges in CLL treatment.

Experts discuss financial challenges of BTK inhibitor therapy.

A panel of experts discuss combination regimens with BTK inhibitors.

A discussion on therapeutic decision-making in CLL and the role of real-world evidence.

Experts discuss leveraging MAICs for decision-making when choosing a CLL BTK inhibitor.

A panel of experts discuss optimizing therapy sequencing in CLL.

A conversation on how to empower patients and the considerations for BTK inhibitor adherence.

Specialists discuss factors influencing the choices of second-generation BTK monotherapy.

Experts evaluate the value of BTK inhibitors in CLL treatment.

A panel of experts provide an overview of BTK inhibitors for the treatment of patients with chronic lymphocytic leukemia.

Experts on the treatment of chronic lymphocytic leukemia discuss recent trends and innovations in the therapeutic landscape.